Most drugs that slow a racing heart also drop your blood pressure, which is precisely the wrong trade-off in POTS, where blood pressure is often already struggling to hold up against gravity. Ivabradine is the exception. It lowers heart rate through a single, narrow mechanism that leaves blood pressure untouched, and that one property is why a medication originally designed for heart failure and angina has become one of the more talked-about options in POTS over the last decade. This post covers how it works, what the trial evidence actually shows, the more recent long-COVID data, how it is dosed, what to watch for, and how it tends to be prescribed in the UK. As with low-dose naltrexone or salt, the evidence is real but still thin, and ivabradine is a tool for a particular kind of patient rather than a universal fix.

The mechanism, in plain language

Your heart has its own pacemaker, the sinoatrial node, and the rate at which it fires is governed in large part by an ion current with the genuinely technical name of the “funny” current, written I-f. Ivabradine selectively blocks this current. The practical consequence is that the pacemaker depolarises more slowly, so the heart beats less often, and it does this without touching the force of contraction, the blood vessels, or blood pressure.

That selectivity is the whole point. In POTS, the problem on standing is an excessive rise in heart rate, not low blood pressure as such (POTS is defined by tachycardia in the absence of orthostatic hypotension). Beta-blockers can blunt the heart rate too, but they do it by dampening the sympathetic nervous system more broadly, which often brings fatigue, low blood pressure, and sometimes sleep disturbance along with it. Ivabradine targets only the rate, which is why it appeals in a condition where the tachycardia is the symptom you most want gone and the side-effect budget for extra fatigue is essentially zero.

There is also a tentative second mechanism worth flagging. In the randomised trial discussed below, patients on ivabradine showed a smaller rise in standing noradrenaline than those on placebo, which the authors suggested might reflect some down-regulation of sympathetic tone rather than pure rate control. This is unproven and was described as unprecedented by the accompanying editorial, so treat it as an interesting thread rather than an established fact.

What the trial evidence actually shows

For years the evidence for ivabradine in POTS was entirely uncontrolled: case series and retrospective reviews, encouraging but unblinded and prone to regression to the mean. The early case series from around 2010 to 2011 reported symptom improvement in roughly 55 to 70 per cent of patients and reduced fatigue in about 70 per cent, with low doses (2.5 mg once daily) often sufficient. Useful signals, but not the kind of evidence that changes guidelines.

That changed in 2021. Taub and colleagues published the first randomised, double-blind, placebo-controlled crossover trial of ivabradine in POTS (Journal of the American College of Cardiology, 2021). It was small, 22 patients with hyperadrenergic POTS randomised to ivabradine or placebo for a month each with a washout between, but it was properly controlled. Ivabradine was superior to placebo at reducing heart rate and improved some quality-of-life measures (physical and social functioning), with the marginal reduction in standing noradrenaline noted above. The accompanying JACC editorial (Raj and Sheldon) called it an important accomplishment given how little high-quality data exists in this field, while cautioning that the trial could not show whether ivabradine beats beta-blockers, the comparison that actually matters in clinic. A head-to-head trial against propranolol was flagged as launching around then (NCT04186286).

A 2018 review had already concluded that ivabradine lowered heart rate and gave symptomatic relief without affecting blood pressure, and a retrospective analysis the same year reported symptom improvement in nearly 70 per cent of adolescents at around 0.1 mg/kg twice daily.

The randomised evidence is a single small trial in one POTS subtype. One recent review put it bluntly, that in the absence of a prospective comparator study ivabradine should not be considered a first-line drug for POTS. It is best read as a well-supported second-line option, particularly where beta-blocker side effects are the limiting factor.

The long-COVID data

The newer interest comes from post-viral POTS. A 2026 cohort of 55 post-COVID POTS patients started on 5 mg of ivabradine twice daily reported significant overall symptom improvement in 78 per cent within seven days, with palpitations improving in around 88 per cent and lightheadedness or pre-syncope in around 76 per cent, alongside significant reductions in resting and standing heart rate. This is observational, not randomised, and the rapid response should be read with the usual caution about open-label cohorts. But it is directly relevant if your POTS began after a viral infection, and it sits within the wider picture covered in long COVID, ME/CFS, POTS and dysautonomia. The mechanistic fit is straightforward: if your dominant problem is an inappropriately fast heart on standing rather than blood pooling or low pressure, a clean rate-control drug is a logical match.

Dosing

Across the trial and clinic literature the pattern is consistent. Ivabradine is typically started low, at 2.5 to 5 mg twice daily, and titrated up to a maximum of 7.5 mg twice daily based on symptom response and heart rate. In the Taub trial most patients started at 5 mg twice daily, with a minority at 2.5 mg; doses were adjusted up or down within that range during titration. Lower starting doses are common in POTS than in the cardiac conditions ivabradine was designed for, and some patients do well on 2.5 mg once daily.

A few practical points that recur in the patient and clinic literature: take it with food, avoid grapefruit (it raises drug levels), and expect any benefit to show quickly, often within days rather than weeks, which is unusual and makes it relatively easy to judge whether it is working for you. Because it is metabolised through the same liver pathway as several other drugs, the interaction list matters, so a pharmacist check against your other medications is worth doing.

Side effects and who should avoid it

Ivabradine is generally well tolerated. In the pooled case-series data, of 124 patients assessed only 3 stopped because of side effects. The most common are mild: dizziness, nausea, headache, fatigue, and a distinctive visual symptom called phosphenes, brief flashes or halos of brightness, which arise because the same I-f current exists in the retina. Phosphenes are usually mild and often settle, but they are the side effect most specific to this drug and worth knowing about in advance so they don’t alarm you.

The more serious considerations are about who should not take it. Ivabradine can cause or worsen bradycardia, so it is not suitable if your resting heart rate is already low. It can affect cardiac rhythm and is contraindicated in certain conduction problems and in significant cardiac disease, which is one reason initiation usually sits with a specialist. It is teratogenic and must not be used in pregnancy, and effective contraception is needed while taking it, an important point given POTS predominantly affects women of reproductive age. Anyone with liver impairment or on interacting medications needs specialist oversight.

How it’s prescribed in the UK

Ivabradine is licensed in the UK for heart failure and angina, not for POTS, so its use here is off-label. In practice that means it is almost always initiated by a specialist (a cardiologist or an autonomic clinic) rather than started by a GP, with ongoing prescribing sometimes handed to the GP under a shared-care arrangement once you are stable on a dose. If you think ivabradine might suit you, the realistic route is a referral to a clinician who manages POTS, and the appointment preparation guide covers how to frame that conversation, including bringing objective data such as your NASA lean test results to make the case for rate control concrete.

It is worth being clear with yourself about subtype before pushing for it. Ivabradine makes most sense when the dominant problem is tachycardia, and it is the hyperadrenergic and post-viral patients in whom the evidence is strongest. If your main issue is blood pooling and low volume, salt, fluid and compression and possibly fludrocortisone address the underlying problem more directly, and rate control alone may disappoint.

What this all adds up to

Ivabradine occupies an unusual and useful niche: it does one thing, slow the heart, cleanly, without the blood-pressure and fatigue costs that make beta-blockers a mixed blessing in POTS. The evidence is genuinely positive but genuinely limited, one small randomised trial in hyperadrenergic POTS, supportive case series, and a promising but uncontrolled post-COVID cohort. That is enough to make it a sensible second-line option, especially for tachycardia-dominant or post-viral POTS and for people who could not tolerate beta-blockers, but not enough to call it first-line, and the comparison that would settle that question has not yet reported.

Ivabradine treats the symptom (the fast heart) rather than the cause, so it works best layered on top of the volume foundation of salt, fluid and compression rather than instead of it. And because it works fast and is well tolerated, it is one of the easier POTS drugs to trial and judge, but it is specialist-initiated, off-label, and unsafe in pregnancy, so it belongs in a properly supervised plan rather than a self-directed experiment.

Ivabradine for POTS: what the evidence says and how it's used